Veterinary Market Transparency Gap: Private Equity Tweaks Ownership Rules

The UK's Competition and Markets Authority (CMA) has raised the stakes by loosening ownership disclosure rules for veterinary services, potentially amplifying private equity's grip on the market.

CMA's New Transparency Pivot

The regulator found that over 60% of UK veterinary practices are controlled by six major groups: CVS, Pets at Home, Medivet, IVC, VetPartners, and Linnaeus (a Mars Petcare subsidiary). The revised draft permits clinics to list a “network or group” name rather than the ultimate parent company.

Private Equity's Deepening Footprint

■Prices are on average 16.6% higher at large corporate clinics compared with independent practices.

■The sector is valued at £6.3 bn, yet this figure masks inefficiencies stemming from limited competition.

■Private equity firms back CVS, Pets at Home, and others, driving a consolidation wave.

Pricing Dynamics and Consumer Impact

■Independent vets charge roughly 16.6% less for comparable services.

■Lack of clear ownership hampers pet owners' ability to assess true costs and alternatives.

■The perception of “local” care is eroded as large groups hide behind familiar brand names.

Potential Regulatory Backlash

■The Progressive Veterinary Association (PVA) has announced a judicial review of the new rules.

■While the CMA argues that recognizable brand names suffice for consumers, the PVA stresses that ultimate ownership data is essential for informed decision‑making.

Market Players' Strategic Responses

■Large groups plan to boost marketing spend on brand visibility to cement competitive advantage.

■Independent clinics are launching awareness campaigns emphasizing transparency and price competition.

■Investors note that consolidation could lift profit margins in the long run, but regulatory uncertainty may add a risk premium.

The opacity in ownership creates a durable risk of price stickiness and reduced competition. As private‑equity‑backed veterinary chains expand, consumer choice becomes clouded, and the CMA's softened stance may further entrench this trend. Stakeholders should monitor regulatory developments and potential legal challenges closely, as they will shape the sector’s risk‑return profile.